<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00106379</url>
  </required_header>
  <id_info>
    <org_study_id>GS-104-0235</org_study_id>
    <nct_id>NCT00106379</nct_id>
  </id_info>
  <brief_title>Tenofovir DF (Disoproxil Fumarate) in Combination With Emtricitabine in HIV-1 Patients</brief_title>
  <official_title>A Phase 4, Single-Arm Study to Evaluate the Safety, Antiviral Activity and Pharmacokinetics of Tenofovir Disoproxil Fumarate in Combination With Emtricitabine in HIV-1 Infected Patients Experiencing Various Degrees of Renal Impairment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to provide long-term clinical safety and efficacy data for&#xD;
      tenofovir disoproxil fumarate and emtricitabine in HIV-infected patients experiencing various&#xD;
      degrees of renal impairment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study is as follows:&#xD;
&#xD;
        -  To evaluate the safety and tolerability of tenofovir following administration of&#xD;
           tenofovir disoproxil fumarate 300 mg for 48 weeks in HIV-infected patients experiencing&#xD;
           various degrees of renal impairment.&#xD;
&#xD;
      The secondary objectives of this study are as follows:&#xD;
&#xD;
        -  To evaluate the safety and tolerability of emtricitabine following administration of&#xD;
           emtricitabine 200 mg for 48 weeks in HIV-infected patients experiencing various degrees&#xD;
           of renal impairment.&#xD;
&#xD;
        -  To evaluate the efficacy of tenofovir disoproxil fumarate in combination with&#xD;
           emtricitabine in renally-impaired HIV-infected patients.&#xD;
&#xD;
        -  To evaluate the pharmacokinetics of tenofovir and emtricitabine in renally-impaired&#xD;
           HIV-infected patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2004</start_date>
  <completion_date type="Actual">January 2007</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HIV-1 infection</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>HIV-1 infection in renally impaired HIV infected patients</measure>
  </secondary_outcome>
  <enrollment>52</enrollment>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Truvada (tenofovir DF + emtricitabine)</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Emtriva (emtricitabine)</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Viread (tenofovir DF)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients must meet all of the following inclusion criteria to be eligible for participation&#xD;
        in the study.&#xD;
&#xD;
          -  HIV-1 infection&#xD;
&#xD;
          -  Either antiretroviral therapy-naive requiring antiretroviral treatment with HIV-1 RNA&#xD;
             greater than 400 copies/mL or antiretroviral therapy-experienced on a stable&#xD;
             antiretroviral regimen for at least 3 mos. with HIV-1 RNA less than or equal to 50&#xD;
             copies/mL at screening.&#xD;
&#xD;
          -  No active opportunistic infection within 45 days prior to baseline.&#xD;
&#xD;
          -  Able to understand and sign the informed consent form and comply with the study.&#xD;
&#xD;
          -  Stable renal impairment within the four defined groups for at least 3 mos., based on&#xD;
             creatinine clearance (Cockcroft-Gault method).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patients who meet any of the following are not to be enrolled in this study.&#xD;
&#xD;
          -  Women who are pregnant or breastfeeding&#xD;
&#xD;
          -  Fanconi syndrome or multiple myeloma, tertiary hyperparathyroidism, malignancy (with&#xD;
             the exception of basocellular carcinoma) or myeloproliferative disorder.&#xD;
&#xD;
          -  Women of childbearing potential who are unwilling to use an effective contraceptive&#xD;
             method during the study&#xD;
&#xD;
          -  Contraindications to tenofovir DF, emtricitabine or efavirenz&#xD;
&#xD;
          -  Undergoing treatment for tuberculosis&#xD;
&#xD;
          -  Using atazanavir&#xD;
&#xD;
          -  Prior history of mutation M184V, K65R or T69 insertion&#xD;
&#xD;
          -  Z-score on pre-baseline DEXA scan less than -2.5&#xD;
&#xD;
          -  The following laboratory values within 30 days prior to study entry: *absolute&#xD;
             neutrophil count (ANC) less than 750/mm3, *hemoglobin less than 9.0 g/dL, *platelet&#xD;
             count less than 50,000/mm3, *AST (SGOT) or ALT (SGPT) less than 5 x ULN and *CD4 cell&#xD;
             count less than 100/mm3.&#xD;
&#xD;
          -  Use of nephrotoxic agents or competitors with renal excretions, including&#xD;
             aminoglycoside antibiotics, intravenous amphotericin B, cidofovir, cisplatin,&#xD;
             foscarnet, intravenous pentamidine, probenecid or other agents with significant&#xD;
             nephrotoxic potential&#xD;
&#xD;
          -  Clinically significant cardiac, pulmonary or gastrointestinal disorder&#xD;
&#xD;
          -  Alcohol or drug abuse that could hinder compliance with the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Gary Richmond, MD</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33316</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Treasure Coast Infectious Disease Consultants</name>
      <address>
        <city>Vero Beach</city>
        <state>Florida</state>
        <zip>32960</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ronald Reisler, MD</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fernando Garcia, MD</name>
      <address>
        <city>Harlingen</city>
        <state>Texas</state>
        <zip>78550</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.truvada.com</url>
    <description>Truvada website</description>
  </link>
  <link>
    <url>http://www.gilead.com</url>
    <description>Gilead website</description>
  </link>
  <link>
    <url>http://www.viread.com</url>
    <description>Viread website</description>
  </link>
  <link>
    <url>http://www.gilead.com/pdf/emtriva_pi.pdf</url>
    <description>Emtriva website</description>
  </link>
  <verification_date>April 2008</verification_date>
  <study_first_submitted>March 23, 2005</study_first_submitted>
  <study_first_submitted_qc>March 23, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 24, 2005</study_first_posted>
  <last_update_submitted>February 1, 2010</last_update_submitted>
  <last_update_submitted_qc>February 1, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 2, 2010</last_update_posted>
  <keyword>HIV-1</keyword>
  <keyword>Treatment Naive</keyword>
  <keyword>Treatment Experienced</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
    <mesh_term>Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

